Prime-Target Vaccination in Malaria

Prime-Target Vaccination in Malaria


  1. Can a more protective liver-stage vaccine against P. falciparum malaria be identified by assessing antigens using transgenic parasite technology combined with sequencing of parasite peptides eluted from MHC molecules?
  2. Can this liver-stage vaccine be improved by combining it with an aw virus-like particle-based anti-sporozoite vaccine?
  3. How can these pre-erythrocytic components be efficiently integrated with anti-blood-stage and anti-sexual stage vaccine components to develop a highly effective multi-component malaria vaccine?

PI Institution(s)

Principal Investigator (PI)

Funding source(s)

Key facts

  • Dates
    Jun 2016 to Nov 2017
    Funding amount
    Funding information
    201,600 GBP

MESA tags

  • Methodology
    Basic science, Product development & clinical research
    Tools for elimination